SUMMARY The cytotoxic T cell response to Epstein-Barr virus as measured by the regression assay was found to be impaired in a group of patients with active rheumatoid arthritis (RA). When these patients responded clinically to treatment with sulphasalazine there was a concomitant increase in the strength of this virus specific T 
Patients with rheumatoid arthritis (RA) show abnormal responses to infection by Epstein-Barr (EB) virus. Thus humoral responses are characterised by raised titres of antibodies to EB virus capsid, early and nuclear antigens,1 2 and by a higher incidence and titre of antibodies to the rheumatoid arthritis nuclear antigen (RANA) .Y This last antigen is now believed to be identical to one of the EB virus encoded nuclear antigens. 6 A number of abnormalities in the cellular response to EB virus have also been described. who had no detectable regression before treatment, had clear regression in two out ofsix ofthe wells seeded at the highest cell density after treatment, so that although a 50% end point was not achieved, this change is still indicated in the figure.) (Table 1) , and when the strength of the EB virus specific cytotoxic T cell response was measured in these patients there was a significant increase in nine of the 14 patients tested. This included four patients in whom regression was undetectable before treatment. It is worth emphasising that such changes are not seen in normal individuals, who invariably show very stable levels of regression when tested repeatedly over several years. 22 As additional evidence of a relation between disease activity and impaired regression, several other observations were informative: the incidence of patients with regression outside the normal range was higher in the group of RA patients with active disease (six of 14) than in the group seen routinely in outpatients and not taking disease modifying agents (six of 31), while in a further group of 10 patients hospitalised because of severe RA six had undetectable regression (unpublished results). Changes in regression together with disease activity were also striking in two particular patients: one (who presented with severe active disease including weight loss and lymphadenopathy) had undetectable regression initially, but showed regression in the normal range when he achieved and maintained a complete remission; a second patient who had regression in the normal range initially suffered a severe exacerbation of RA with widespread synovitis while taking sulphasalazine, and was then found to have undetectable regression. Finally, although a wide range in the strength of regression is seen in normal individuals, it is of interest that a significant correlation could still be found between the serum CRP (taken as a sensitive measurement of disease activity23) and the strength of regression measured before and after treatment.
The second group of experiments was designed to show whether the abnormal EB virus specific T cell response seen in RA was peculiar to this disease or was also present in patients with other arthropathies. It was clear from the results that a number of patients with typical seronegative arthropathies also showed significantly impaired regression; since only a few patients were investigated and no prospective study performed a relation between disease activity and impairment could not be discerned, and this point will require further study. In contrast, almost all the patients with gout or osteoarthritis, attending the same clinic, had regression within the normal range (the single exception is unexplained but was a consistent finding in repeated assays). 
